Skip to main content

Advertisement

SpringerLink
Log in

Serum integrin-linked kinase (sILK) concentration and survival in non-small cell lung cancer: a pilot study

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

Integrin-linked kinase (ILK) is an intracellular signaling protein critically involved in cellular growth and motility. In non-small cell lung cancer (NSCLC), increased ILK expression has been associated with decreased recurrence-free and overall survival. Recently, ILK has also been detected in the serum of NSCLC patients.

Objective

To assess the prognostic impact of preoperative serum ILK (sILK) concentration on overall survival in surgically amenable NSCLC.

Patients and methods

Preoperative sILK was quantified by ELISA in 50 newly diagnosed NSCLC patients. After surgery, patients were followed-up for a median interval of 2.5 years.

Results

Serum ILK concentrations ranged from 0 to 2.44 ng/ml. Mean sILK was around 2.3 times higher in the 16 patients who died as compared to the 34 patients who survived (1.04 vs. 0.45 ng/ml, p = 0.001). In univariate time-to-event analysis, increased sILK was associated with adverse survival [Hazard ratio (HR): 4.03, 95 % CI: 2.00–8.13, p < 0.001]. This association prevailed after multivariable adjustment for several clinical, demographic, and laboratory parameters (HR: 3.85, 95 % CI: 1.53–9.72, p = 0.004).

Conclusions

Serum ILK shows potential as a novel strong and independent prognostic marker for postoperative survival in surgically amenable NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  2. (ONS) OoNS. Cancer survival in england: patients diagnosed 2005–2009 followed up to 2010. ONS Stat Bull. 2011.

  3. Baldwin DR, White B, Schmidt-Hansen M, Champion AR, Melder AM. Diagnosis and treatment of lung cancer: summary of updated NICE guidance. BMJ. 2011;342:d2110.

    Article  CAS  PubMed  Google Scholar 

  4. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer. 2005;5(1):51–63.

    Article  CAS  PubMed  Google Scholar 

  5. Watzka SB, Setinek U, Huber M, Cantonati H, Lax F, Watson S, et al. Reactivity of integrin-linked kinase in human mesothelial cell proliferation. Interact Cardiovasc Thorac Surg. 2008;7(1):107–10.

    Article  PubMed  Google Scholar 

  6. Watzka SB, Setinek U, Stubenberger EB, Totsch M, Dekan G, Marcher M, et al. Integrin-linked kinase, phosphorylated AKT and the prognosis of malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2011;39(2):180–4.

    Article  PubMed  Google Scholar 

  7. Okamura M, Yamaji S, Nagashima Y, Nishikawa M, Yoshimoto N, Kido Y, et al. Prognostic value of integrin beta1-ILK-pAkt signaling pathway in non-small cell lung cancer. Hum Pathol. 2007;38(7):1081–91.

    Article  CAS  PubMed  Google Scholar 

  8. Takanami I. Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer. 2005;5(5):1.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Ahmed N, Riley C, Oliva K, Stutt E, Rice GE, Quinn MA. Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. J Pathol. 2003;201(2):229–37.

    Article  CAS  PubMed  Google Scholar 

  10. Ito R, Oue N, Zhu X, Yoshida K, Nakayama H, Yokozaki H, et al. Expression of integrin-linked kinase is closely correlated with invasion and metastasis of gastric carcinoma. Virchows Arch. 2003;442(2):118–23.

    CAS  PubMed  Google Scholar 

  11. Li R, Liu B, Yin H, Sun W, Yin J, Su Q. Overexpression of integrin-linked kinase (ILK) is associated with tumor progression and an unfavorable prognosis in patients with colorectal cancer. J Mol Histol. 2013;44(2):183–9.

    Google Scholar 

  12. Watzka SB, Posch F, Pass HI, Huflejt M, Bernhard D, Hannigan GE, et al. Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2011;142(2):384–9.

    Article  CAS  PubMed  Google Scholar 

  13. Janes H, Longton G, Pepe M. Accommodating covariates in ROC analysis. Stata J. 2009;9(1):17–39.

    PubMed Central  PubMed  Google Scholar 

  14. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer. 2005;41(12):1690–6.

    Article  PubMed  Google Scholar 

  15. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 2012;10:51.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Watzka SB, Rauscher-Potsch I, Stubenberger E, Getman V, Setinek U, Totsch M, et al. Immunoreactivity of integrin-linked kinase in primary non-small-cell lung cancer and survival after curative resection. Eur J Cardiothorac Surg. 2010;38(3):254–9.

    Article  PubMed  Google Scholar 

  17. McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase–essential roles in physiology and cancer biology. J Cell Sci. 2008;121(Pt 19):3121–32.

    Article  CAS  PubMed  Google Scholar 

  18. Durbin AD, Hannigan GE, Malkin D. Oncogenic ILK, tumor suppression and all that JNK. Cell Cycle. 2009;8(24):4060–6.

    Article  CAS  PubMed  Google Scholar 

  19. Ahmed N, Oliva K, Rice GE, Quinn MA. Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma. Clin Cancer Res. 2004;10(7):2415–20.

    Article  CAS  PubMed  Google Scholar 

  20. Watzka SB, Posch F, Pass HI, Flores RM, Hannigan GE, Bernhard D, et al. Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure. Eur J Cardiothorac Surg. 2013;43(5):940–5.

    Google Scholar 

  21. Hegmans JP, Bard MP, Hemmes A, Luider TM, Kleijmeer MJ, Prins JB, et al. Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol. 2004;164(5):1807–15.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569–79.

    CAS  PubMed  Google Scholar 

  23. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122(3):1037–57.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was funded by an unrestricted grant of the Karl Landsteiner Institute for Thoracic Oncology (Sanatoriumstrasse 2, 1140 Vienna, Austria, www.karl-landsteiner.at/institute/thorokale_onkologie.html). The authors would like to thank the study patients for their participation and support.

Conflict of interest

The authors have no conflicting interests to declare.

Author information

Authors and Affiliations

  1. Division of Thoracic Surgery, Karl Landsteiner Institute for Thoracic Oncology, Otto Wagner Hospital, Sanatoriumstrasse 2, 1140, Vienna, Austria

    F. Posch, M. R. Mueller & S. B. Watzka

  2. Institute of Pathology and Bacteriology, Otto Wagner Hospital, Vienna, Austria

    U. Setinek

  3. Division of Thoracic Surgery, Mount Sinai School of Medicine, New York, NY, USA

    R. M. Flores

  4. Cardiac Surgery Research Laboratory, Division of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria

    D. Bernhard

  5. Centre for Cancer Research, Monash Institute of Medical Research, Monash University, Clayton, Australia

    G. E. Hannigan

  6. Division of Surgery, Paracelsus Medical University, Salzburg, Austria

    S. B. Watzka

Authors
  1. F. Posch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. Setinek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. M. Flores
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Bernhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. E. Hannigan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. R. Mueller
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. B. Watzka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. B. Watzka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Posch, F., Setinek, U., Flores, R.M. et al. Serum integrin-linked kinase (sILK) concentration and survival in non-small cell lung cancer: a pilot study. Clin Transl Oncol 16, 455–462 (2014). https://doi.org/10.1007/s12094-013-1101-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-013-1101-6

Keywords

Search

Navigation